Current Hypertension Reports

, Volume 12, Issue 4, pp 307–312 | Cite as

Systolic Pressure, Diastolic Pressure, or Pulse Pressure as a Cardiovascular Risk Factor in Renal Disease

  • José A. García-DonaireEmail author
  • Luis M. Ruilope


Chronic kidney disease is a leading global health problem with an increasing prevalence. Hypertension is present in most patients with chronic kidney disease, and hypertension-related nephrosclerosis is a top cause of progressive renal damage and end-stage renal disease. Systolic blood pressure (BP) and pulse pressure, together with nocturnal BP, are the most important factors favoring the progression of renal failure. Consequently, strict control of BP and other cardiovascular risk factors is required, including an adequate degree of suppression of the renin-angiotensin system in every patient.


Systolic blood pressure Diastolic blood pressure Blood pressure Hypertension Chronic kidney disease End-stage renal disease Renal failure Renin-angiotensin system 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Snyder JJ, Collins AJ: KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999–2004. Am J Nephrol 2009, 30:44–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Mancia G, De Backer G, Dominiczak A, et al.: 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751–1762CrossRefPubMedGoogle Scholar
  3. 3.
    Williams B: The changing face of hypertension treatment: treatment strategies from the 2007 ESH/ESC Hypertension Guidelines. J Hypertens 2009, 27(Suppl 3):S19–S26.CrossRefGoogle Scholar
  4. 4.
    Tonelli M, Wiebe M, Culleton B, et al.: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006, 17:2034–2047.CrossRefPubMedGoogle Scholar
  5. 5.
    Ruilope LM, Lahera V, Rodicio JL, et al.: Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 1994, 23:3–9.PubMedGoogle Scholar
  6. 6.
    Ruilope LM, Campo C, Rodicio JL: Relationship between blood pressure and renal function. J Hypertens Suppl 1994, 12:S55–59.PubMedGoogle Scholar
  7. 7.
    Hovind P, Rossing P, Tarnow L, et al.: Progression of diabetic nephropathy. Kidney Int 2001, 59:702–709CrossRefPubMedGoogle Scholar
  8. 8.
    Fisher CM: The ascendancy of diastolic blood pressure over systolic. Lancet 1985, 11:1349–1350.CrossRefGoogle Scholar
  9. 9.
    White WB: Systolic versus diastolic blood pressure versus pulse pressure. Curr Cardiol Rep 2002, 4:463–467.CrossRefPubMedGoogle Scholar
  10. 10.
    Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey 1988–1991. Hypertension 1995, 25:305–313.PubMedGoogle Scholar
  11. 11.
    Black HR: The paradigm has shifted, to systolic blood pressure. Hypertension 1999, 34:386–387.PubMedGoogle Scholar
  12. 12.
    Sever P: Abandoning diastole. BMJ 1999, 318:1773.PubMedGoogle Scholar
  13. 13.
    Amar J, Chamontin B: Cardiovascular risk factors, atherosclerosis and pulse pressure. Adv Cardiol 2007, 44:212–222.CrossRefPubMedGoogle Scholar
  14. 14.
    Benetos A, Zureik M, Morcet J, et al.: A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000, 35:673–680.CrossRefPubMedGoogle Scholar
  15. 15.
    Staessen JA, Gasowski J, Wang JG, et al.: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355:865–872.CrossRefPubMedGoogle Scholar
  16. 16.
    Kannel WB: Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999, 138:205–210.CrossRefPubMedGoogle Scholar
  17. 17.
    Strandberg TE, Pitkala K: What is the most important component of blood pressure: systolic, diastolic or pulse pressure? Curr Opin Nephrol Hypertens 2003, 12:293–297.CrossRefPubMedGoogle Scholar
  18. 18.
    Franklin SS: Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. J Hypertens 1999, 17:S29–S36.Google Scholar
  19. 19.
    Schillaci G, Pirro M, Mannarino MR, et al.: Relation between renal function within the normal range and central and peripheral arterial stiffness in hypertension. Hypertension 2006, 48:616–621.CrossRefPubMedGoogle Scholar
  20. 20.
    Asmar R: Benefits of blood pressure reduction in elderly patients. J Hypertens Suppl 2003, 21:S25–S30.PubMedGoogle Scholar
  21. 21.
    Franklin SS: Systolic blood pressure: It’s time to take control. Am J Hypertens 2004, 17:49S–54S.CrossRefPubMedGoogle Scholar
  22. 22.
    Laurent S, Cockcroft J, Van Bortel L, et al.; European Network for Non-Invasive Investigation of Large Arteries: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588–2605.CrossRefPubMedGoogle Scholar
  23. 23.
    Benetos A, Safar M, Rudnichi A, et al.: Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997, 30:1410–1415.PubMedGoogle Scholar
  24. 24.
    Gasowski J, Fagard RH, Staessen JA, et al.; INDANA Project Collaborators: Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. J Hypertens 2002, 20:145–151.CrossRefPubMedGoogle Scholar
  25. 25.
    Darne B, Girerd X, Safar M, et al.: Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension 1989, 13:392–400.PubMedGoogle Scholar
  26. 26.
    Lewington S, Clarke R, Qizilbash N, et al.; Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.CrossRefPubMedGoogle Scholar
  27. 27.
    • Lawes CMM, Van der Horn S, Rodgers A: Global burden of blood pressure related disease, 2001. Lancet 2008, 371:1513–1518. This study assesses the extent and global distribution of the burden of BP-related disease. It concludes that low-income and middle-income countries and middle-aged, prehypertensive people cause most of the disease burden.CrossRefPubMedGoogle Scholar
  28. 28.
    Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.CrossRefPubMedGoogle Scholar
  29. 29.
    Sever P: Is systolic blood pressure all that matters? Yes. BMJ 2009, 339:b2665.CrossRefPubMedGoogle Scholar
  30. 30.
    O’Brien E: Is systolic blood pressure all that matters? No. BMJ 2009, 339:b2669.CrossRefPubMedGoogle Scholar
  31. 31.
    Franklin SS, Jacobs M, Wong ND, et al.: Predominance of isolated systolic hypertension among middle aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES III). Hypertension 2001, 37:869–874.PubMedGoogle Scholar
  32. 32.
    •• Williams B, Lindholm LH, Sever P: Systolic pressure is all that matters. Lancet 2008, 371:2219–2222. These authors review evidence supporting the hypothesis that SBP contributes more of the huge global disease burden attributable to hypertension than does DBP.CrossRefPubMedGoogle Scholar
  33. 33.
    •• Mancia G, Laurent S, Agabiti-Rosei E, et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009, 18:308–347. This is an important review of current guideline recommendations according to results of the latest trials.CrossRefPubMedGoogle Scholar
  34. 34.
    •• Zanchetti A, Grassi G, Mancia G: When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009, 27:923–934. This paper is a critical discussion of the most debated items included in the most recent international guidelines.CrossRefPubMedGoogle Scholar
  35. 35.
    Stamler J: Epidemiology of coronary heart disease. Med Clin North Am 1973, 57:5–46.PubMedGoogle Scholar
  36. 36.
    Schram MT, Kostense PJ, Van Dijk RA, et al.: Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. J Hypertens 2002, 20:1743–1751.CrossRefPubMedGoogle Scholar
  37. 37.
    Martins D, Tareen N, Pan D, Norris K: The relationship between body mass index and pulse pressure in older adults with isolated systolic hypertension. Am J Hypertens 2002, 15:538–543.CrossRefPubMedGoogle Scholar
  38. 38.
    Abramson JL, Weintraub WS, Vaccarino V: Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002, 39:197–202.CrossRefPubMedGoogle Scholar
  39. 39.
    Knudsen ST, Poulsen PL, Hansen KW, et al.: Pulse pressure and diurnal blood pressure variation: association with micro- and macrovascular complications in type 2 diabetes. Am J Hypertens 2002, 15:244–250.CrossRefPubMedGoogle Scholar
  40. 40.
    Kato J, Kitamura K, Uemura T, et al.: Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res 2002, 25:887–892.CrossRefPubMedGoogle Scholar
  41. 41.
    Antikainen RL, Jousilahti P, Vanhanen H, Tuomilehto J: Excess mortality associated with increased pulse pressure among middle-aged men and women is explained by high systolic blood pressure. J Hypertens 2000, 18:417–423.CrossRefPubMedGoogle Scholar
  42. 42.
    Strandberg TE, Salomaa VV, Vanhanen HT, et al.: Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predictors of mortality during a follow-up of up to 32 years. J Hypertens 2002, 20:399–404.CrossRefPubMedGoogle Scholar
  43. 43.
    Domanski M, Mitchell G, Pfeffer M, et al.; MRFIT Research Group: Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002, 287:2677–2683.CrossRefPubMedGoogle Scholar
  44. 44.
    Buckalew VM, Berg RL, Wang SR, et al.: Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996, 28:811–821.CrossRefPubMedGoogle Scholar
  45. 45.
    • Redon J, Plancha E, Swift P, et al.: Nocturnal blood pressure and progression to end-stage renal disease or death in nondiabetic chronic kidney disease stages 3 and 4. J Hypertens 2010, 28:602–607. This interesting study assesses the role of office and ambulatory blood pressure measurements on the development of ESRD in nondiabetic CKD.CrossRefPubMedGoogle Scholar
  46. 46.
    Agarwal R, Anderson MJ: Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006, 69:1175–1180.CrossRefPubMedGoogle Scholar
  47. 47.
    Zager PG, Nicolie J, Brown RH, et al.: “U” Curve association of blood pressure and mortality in haemodialysis patients. Kidney Int 1998, 54:561–569.CrossRefPubMedGoogle Scholar
  48. 48.
    Agarwal R: Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:830–837.CrossRefPubMedGoogle Scholar
  49. 49.
    Haider AW, Larson MG, Franklin SS, Levy D: Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003, 138:10–16.PubMedGoogle Scholar
  50. 50.
    Tozawa M, Iseki K, Oshiro S, et al.: Evidence for elevated pulse pressure in patients on chronic haemodialysis: A case-control study. Kidney Int 2002, 62:2195–2201.CrossRefPubMedGoogle Scholar
  51. 51.
    Klassen PS, Lowrie EG, Reddan DN, et al.: Association between pulse pressure and mortality in patients undergoing maintenance haemodialysis. JAMA 2002, 287:1548–1555.CrossRefPubMedGoogle Scholar
  52. 52.
    De Nicola L, Minutolo R, Chiodini P et al.: Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int 2006, 69:538–545.CrossRefPubMedGoogle Scholar
  53. 53.
    Manjunath G, Tighiouart H, Ibrahim H et al.: Level of kidney function as a risk factor for atherosclerotic cardiovascular disease in the community. J Am Coll Cardiol 2003, 41:47–55.CrossRefPubMedGoogle Scholar
  54. 54.
    Chen J, Muntner P, Hamm LL et al.: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004 140:167–174.PubMedGoogle Scholar
  55. 55.
    Segura J, Campo C, Ruilope LM: Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 2004, 6(suppl 92):S1–S5.Google Scholar
  56. 56.
    Abbott KC, Bakris GL: What have we learned from the current trials? Med Clin North Am 2004, 88:189–207.CrossRefPubMedGoogle Scholar
  57. 57.
    Gansevoort RT, de Jong PE: The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol 2009, 20:465–468.CrossRefPubMedGoogle Scholar
  58. 58.
    Feringa HH, Karagiannis SE, Chonchol M, et al.: Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 2007, 18:1872–1879.CrossRefPubMedGoogle Scholar
  59. 59.
    Jafar TH, Stark PC, Schmid CH, et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244–252.PubMedGoogle Scholar
  60. 60.
    Kjeldsen S, Julius S: Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 2004, 148:747–754.CrossRefPubMedGoogle Scholar
  61. 61.
    Casas JP, Chua W, Loukogeorgakis S et al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366:2026–2033.CrossRefPubMedGoogle Scholar
  62. 62.
    Solomon SD, Rice MM, Jablonski K, et al.; Prevention of Events with ACE inhibition (PEACE) Investigators: Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006, 114:26–31.CrossRefPubMedGoogle Scholar
  63. 63.
    Bakris GL, Sarafidis PA, Weir MR, et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173–1181.CrossRefPubMedGoogle Scholar
  64. 64.
    Wanner C, Ritz E: Reducing lipids for CV protection in CKD patients—current evidence. Kidney Int Suppl 2008, 111:S24–S28.CrossRefPubMedGoogle Scholar
  65. 65.
    Evans M, Fored CM, Bellocco R, et al.: Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transplant 2009, 24:1908–1918.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Hypertension Unit, Hospital 12 de OctubreMadridSpain

Personalised recommendations